Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ParagonDx granted clearance for warfarin sensitivity test
ParagonDx’s genotyping assay is said to be the first cleared product to deliver results in less than one hour and incorporate human genomic quality controls. The ParagonDx test
ParagonDx’s genotyping assay is said to be the first cleared product to deliver results in less than one hour and incorporate human genomic quality controls. The ParagonDx test
Tecnica Scientifica Service Medical (TSS Medical) has purchased this additional inventory to meet demand in Italy and other EU counties. Andrew Whelan, president and CEO of BioElectronics, said:
The product is available in bottles of 100 and is available for immediate shipment to wholesalers and pharmacies nationwide. Roxane’s ropinirole hydrochloride tablets are AB rated to Requip
Yaz will be launched in all major European markets in autumn 2008. Yaz is said to be the first oral contraceptive on the European market containing the unique
In her new role, Ms Schwalm will have full operating responsibility for leading Eisai Inc., the US commercial operation of Eisai Co., Ltd. She will report to Lonnel
Under the terms of the new collaboration agreement, Spectral will have access to Toray’s distributors in new geographic territories including China, India, Russia and Canada for the sales
Therapy Acceleration Program (TAP) is an innovative program intended to advance therapies with high prospects of providing near-term benefit to patients suffering from blood cancers. The TAP funding
The objective of this dose-ranging study is to support dose selection for Phase III, and to inform the ongoing development of a convenient delivery system for this combination
The device has CE certification from the EU allowing European sales for this non-invasive method for rapid treatment of high-intensity oncologic and neuropathic pain, including pain resistant to
The data show that Raptiva therapy had a sustained effect in those patients who responded to the initial 12-week treatment (82%). A 75% improvement in the disease, as